23ANDME AND ITS USER DATA WILL SOON BELONG TO A PHARMACEUTICAL GIANT

Summary from the TLDR newsletter

23andMe will be sold to Regeneron Pharmaceuticals for $256 million. The sale includes 23andMe's Total Health and Research Services business and biobank of customer data and genetic samples. 23andMe says that customer data is anonymized and stored genetic samples are destroyed when users delete their accounts, but it is unclear how much information is retained. Regeneron's co-founder said that the purchase will further the company's large-scale genetics research into future drugs and treatments. 23andMe has collected genetic samples and data from more than 15 million customers.